Hachem Christine, Morgan Robert, Johnson Michael, Kuebeler Mark, El-Serag Hashem
Houston Center for Quality of Care and Utilization Studies, Health Services Research, Department of Veterans Affairs Medical Center, Houston, Texas, USA.
Am J Gastroenterol. 2009 May;104(5):1241-8. doi: 10.1038/ajg.2009.64. Epub 2009 Apr 7.
Experimental data indicate a possible preventive effect for statins in colorectal cancer (CRC). However, the available epidemiological data are conflicting.
We conducted a nested case-control study of veterans with diabetes in national databases of the Department of Veterans Affairs (VA) and Medicare-linked files. Cases were defined as incident CRC during January 2001-December 2002, sampled on incidence density. VA pharmacy benefits management (PBM) files were used to identify filled prescriptions for statins. Multivariable conditional logistic regression models were used to estimate odds ratios (ORs) after adjusting for potential confounding variables. Stratified analyses were conducted for potential effect modifiers.
A total of 6,080 cases and 24,320 controls were examined. The mean age was 74 years, and the majority of patients were Caucasian (88%) and male (99%). Filled prescriptions of statins were recorded less frequently in cases (49%) than in controls (52%; OR: 0.88; 95% confidence interval (95% CI): 0.83-0.93). This inverse association remained significant after adjusting for inflammatory bowel disease, diabetes severity, cholecystectomy, liver disease, filled prescriptions for sulfonylurea, aspirin or NSAID use, or colorectal evaluation. Simvastatin comprised the majority (87%) of statin-filled prescriptions, and the association with risk of CRC with simvastatin was very similar to that of any statin. No significant associations were observed between the risk of CRC and nonstatin cholesterol (OR: 1.02; 95% CI 0.88-1.18) or triglyceride-lowering medications (OR: 0.96; 95% CI: 0.87-1.05). The significant inverse association was limited to Caucasians, patients without history of polyps, patients aged 65 years and older, and patients with colon cancer (excluding rectum).
The use of statins was associated with a small reduction in the risk of colon cancer in patients with diabetes. However, the causal link is not clear.
实验数据表明他汀类药物对结直肠癌(CRC)可能具有预防作用。然而,现有的流行病学数据存在矛盾。
我们在退伍军人事务部(VA)的国家数据库和与医疗保险相关的文件中,对患有糖尿病的退伍军人进行了一项巢式病例对照研究。病例定义为2001年1月至2002年12月期间发生的CRC,按发病密度抽样。VA药房效益管理(PBM)文件用于识别他汀类药物的已配处方。多变量条件逻辑回归模型用于在调整潜在混杂变量后估计比值比(OR)。对潜在效应修饰因素进行分层分析。
共检查了6080例病例和24320例对照。平均年龄为74岁,大多数患者为白种人(88%)且为男性(99%)。病例中他汀类药物的已配处方记录频率(49%)低于对照(52%;OR:0.88;95%置信区间(95%CI):0.83 - 0.93)。在调整炎症性肠病、糖尿病严重程度、胆囊切除术、肝病、磺脲类药物、阿司匹林或非甾体抗炎药的已配处方使用情况或结直肠评估后,这种负相关仍然显著。辛伐他汀占他汀类药物已配处方的大多数(87%),辛伐他汀与CRC风险的关联与任何他汀类药物的关联非常相似。未观察到CRC风险与非他汀类胆固醇(OR:1.02;95%CI 0.88 - 1.18)或降甘油三酯药物(OR:0.96;95%CI:0.87 - 1.05)之间存在显著关联。显著的负相关仅限于白种人、无息肉病史的患者、65岁及以上的患者以及患有结肠癌(不包括直肠癌)的患者。
他汀类药物的使用与糖尿病患者患结肠癌的风险略有降低有关。然而,因果关系尚不清楚。